Quarterly ResultApr 30, 2026, 04:37 PM
HURA 2025 Net Loss $(30.1)M; Cash $3.6M; Needs Funding
AI Summary
TuHURA Biosciences reported a net loss of $(30.1) million for the year ended December 31, 2025, increasing from $(21.7) million in 2024, with an accumulated deficit of $141.2 million. The company had $3.6 million in cash and cash equivalents as of year-end and expects current funds to last through Q2 and into Q3 2026, necessitating substantial additional funding. The filing also details recent financing activities, including a $15.6 million registered direct offering and a $12.6 million private placement, and the acquisition of Kineta, Inc. in June 2025. This 10-K/A amends the original 10-K to include Part III information and correct errors in the MD&A.
Key Highlights
- Net loss for 2025 was $(30.1) million, up from $(21.7) million in 2024.
- Accumulated deficit reached $141.2 million as of December 31, 2025.
- Cash and cash equivalents stood at $3.6 million at year-end 2025.
- Total operating expenses increased to $31.8 million in 2025 from $17.6 million in 2024.
- Raised approximately $15.6 million gross from December 2025 Registered Direct Offering.
- Secured approximately $12.6 million gross from June 2025 Private Placement.
- Completed the acquisition of Kineta, Inc. on June 30, 2025.
- Liquidity expected to support operations through Q2 and into Q3 2026.